Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 826 across all filing types
Latest filing 2018-11-07 Regulatory Filings
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Information relating to the total number of voting rights and shares making up the capital
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and its primary content is the announcement of the "Total number of outstanding shares as well as its voting rights as of October 31, 2018," citing compliance with French regulatory articles (L. 233-8 II of the French « Code de Commerce » and article 223-16 of the AMF charter). This type of mandatory disclosure regarding share capital structure and voting rights, issued via a press release, is a common regulatory filing. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). While it relates to share capital, it is a specific regulatory disclosure about the count of shares/rights, which often falls under general regulatory announcements or specific share/capital change notifications. Given the context of mandatory disclosure of share count/voting rights, it aligns closely with regulatory reporting requirements. Since there is no specific code for 'Share Count/Voting Rights Disclosure', and it is a formal regulatory announcement, it fits best under the general 'Regulatory Filings' (RNS) category, or potentially 'Share Issue/Capital Change' (SHA) if the focus was on a change, but here it is a periodic report of the current state. However, the specific nature of reporting total shares and voting rights pursuant to AMF rules strongly suggests a mandatory regulatory filing that isn't covered by the more specific codes like DIV or SHA (which usually implies an issuance/buyback). I will classify it as RNS as a general regulatory filing, as it is a mandatory disclosure of share structure data required by the regulator.
2018-11-07 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces that Adocia will present six abstracts at the American Diabetes Association® 78th Scientific Sessions. It details the specific presentations (oral and poster) including dates, times, and authors. This type of announcement, detailing participation in an industry event or conference, is typically classified as a general corporate announcement or a specific type of investor communication. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it is focused on scientific data presentation, it fits best under a general regulatory/corporate announcement category. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for press releases that don't fit the highly specific financial or governance codes. It is not a proxy statement (PSI), dividend notice (DIV), or management change (MANG). It is an announcement of scientific activity, which often accompanies or precedes formal filings, but here it is a standalone press release.
2018-06-14 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that the company, Adocia, will present six abstracts at the 78th Scientific Sessions of the American Diabetes Association (ADA). It details the content of these presentations (oral and poster sessions) and provides general information about the ADA event and the company. This type of announcement, detailing upcoming scientific presentations or key corporate news released via a press release format, most closely aligns with an 'Earnings Release' (ER) if it were financial results, or a general 'Regulatory Filing' (RNS) if no other category fits. Since it is a specific announcement about scientific data presentation rather than a full financial report (10-K, IR), a management discussion (MDA), or a specific capital event, and it is not a transcript (CT) or a presentation deck (IP), the most appropriate general category for a corporate news announcement that doesn't fit the highly specific financial/governance codes is the fallback category, Regulatory Filings (RNS), as it is a formal public disclosure. However, given the context of scientific data being presented at a major conference, it is a form of corporate communication. It is not an ER (no financial results), not an IP (it's an announcement *about* presentations, not the presentation itself), and not an MDA (no detailed management analysis of past performance). It is a formal announcement of corporate activity/data dissemination. RNS is the best fit as a general regulatory announcement/press release fallback.
2018-06-14 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is a press release ('COMMUNIQUE DE PRESSE') published on June 8, 2018, detailing the total number of shares and voting rights as of May 31, 2018. It explicitly cites compliance with French commercial code (Code de Commerce) and the General Regulation of the Autorité des Marchés Financiers (AMF). This type of mandatory disclosure regarding capital structure and voting rights is a specific regulatory filing requirement in France, often related to major shareholding changes or general capital updates. Since it is a formal announcement of a specific, recurring regulatory metric (share count/voting rights) mandated by the regulator (AMF), it fits best under the general 'Regulatory Filings' category (RNS) as there is no specific code for 'AMF Share Count Disclosure'. It is not an Earnings Release (ER), Interim Report (IR), or a Director's Dealing (DIRS). Given the context of mandatory regulatory reporting, RNS is the most appropriate general classification.
2018-06-08 French
Information relating to the total number of voting rights and shares making up the capital
Share Issue/Capital Change Classification · 1% confidence The document is a press release titled "Number of shares and voting rights of ADOCIA as of May, 31 2018," released on June 8, 2018. It explicitly states that it is pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the AMF charter, detailing the total number of outstanding shares and voting rights as of a specific past date (May 31, 2018). This type of mandatory disclosure regarding share capital structure and voting rights is a specific regulatory filing requirement in France, often related to major shareholding changes or periodic updates. While it is a regulatory announcement, it specifically deals with share capital structure and voting rights, which aligns closely with the scope of 'Major Shareholding Notification' (MRQ) or general 'Regulatory Filings' (RNS). However, given the precise nature of reporting outstanding shares and voting rights, it is a specific type of disclosure. Since there is no specific code for 'Share Capital/Voting Rights Disclosure', and it is not a change in ownership threshold (MRQ), nor a dividend (DIV), nor a general share issue (SHA), the most appropriate general regulatory category is RNS. If the document were solely about a director's dealing, it would be DIRS. If it were about a general share issue/buyback, it would be SHA/POS. Since it is a mandatory periodic disclosure of the total share count and voting rights under AMF rules, RNS serves as the best fit among the provided options for a specific regulatory update that isn't covered by other specific codes.
2018-06-08 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces that the CEO will be hosting one-on-one meetings at the "Jefferies 2018 Global Healthcare Conference." This is a typical announcement regarding management participation in an external industry event, intended for investors and analysts. It is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). The most fitting category for an announcement about management engaging with investors/analysts at a conference is Investor Presentation (IP), as these events often involve presenting company strategy and pipeline updates, or potentially Regulatory Filings (RNS) if it were a general announcement. Given the context of management presenting/meeting at a specific investor conference, 'Investor Presentation' (IP) is the closest fit, although 'Regulatory Filings' (RNS) is a possible fallback if the intent is purely informational/non-financial disclosure. Since it details management's schedule for investor engagement, IP is preferred over the general RNS.
2018-06-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.